Suboptimal Vaccination Coverage and Serological Screening in Western Australian Children With Inflammatory Bowel Disease Receiving Immunosuppressive Therapy: An Opportunity for Improvement

Background Patients with inflammatory bowel disease (IBD) face an increased likelihood of severe illnesses, including those caused by vaccine-preventable diseases. Consequently, the purpose of this study was to evaluate both vaccination rates and serological screening in children with IBD in Western Australia, focusing on compliance with routine and additional vaccines, and pre-treatment screening for infections before starting immunosuppressive (IS) treatment. Method The study was conducted at Perth Children's Hospital (PCH) from June 2021 to February 2022, focusing on children aged 0-18 with confirmed IBD diagnoses. Demographic and medical data were collected and matched with immunization records from the Australian Immunisation Register (AIR) to audit compliance with routine childhood vaccinations and additional vaccines (23-valent pneumococcal, human papillomavirus (HPV), and annual influenza). Data from medical records were analyzed for compliance with serologic testing (QuantiFERON TB, Hep B and C, Varicella, and Epstein-Barr virus (EBV)) before initiating IS therapy, which included immunomodulators, biologics, or small molecules. Results Of the 243 patients, 120 (52%) were diagnosed with Crohn's disease and 106 (43%) with ulcerative colitis. A total of 181 patients (74.5%) were treated with immunomodulators, while 62 (26%) received biologic therapies. Incomplete routine vaccination coverage was identified in 71 (29.2%) patients, with no notable differences observed between the IS and non-IS groups (p=0.3). Specific vaccines with incomplete coverage included HPV in 49 (24%) patients, Varicella in 39 (16%) patients, and diphtheria-tetanus-pertussis (DTP in 16 (6.5%) patients. Pre-treatment serological screening was also suboptimal, with the lowest testing rate for EBV at 32 (13.2) patients and the highest for Varicella at 181 (74.6%) patients. Conclusion The results emphasized the importance of targeted interventions to enhance vaccination and screening practices, enhancing disease management, and reducing the possibility of preventable infections in the vulnerable populace.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2024-11-15
DOI
https://doi.org/10.7759/cureus.73744
Citations
1
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.55
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Suboptimal Vaccination Coverage and Serological Screening in Western Australian Children With Inflammatory Bowel Disease Receiving Immunosuppressive Therapy: An Opportunity for Improvement

Zubin Grover, Sibgha Arif, Mir Shabir, Dan Yeoh
1 citations
Cureus
Inflammatory Bowel Disease
0.55
article

Suboptimal Vaccination Coverage and Serological Screening in Western Australian Children With Inflammatory Bowel Disease Receiving Immunosuppressive Therapy: An Opportunity for Improvement

Zubin Grover, Sibgha Arif, Mir Shabir, Dan Yeoh
article en
1 citations

Abstract

Background Patients with inflammatory bowel disease (IBD) face an increased likelihood of severe illnesses, including those caused by vaccine-preventable diseases. Consequently, the purpose of this study was to evaluate both vaccination rates and serological screening in children with IBD in Western Australia, focusing on compliance with routine and additional vaccines, and pre-treatment screening for infections before starting immunosuppressive (IS) treatment. Method The study was conducted at Perth Children's Hospital (PCH) from June 2021 to February 2022, focusing on children aged 0-18 with confirmed IBD diagnoses. Demographic and medical data were collected and matched with immunization records from the Australian Immunisation Register (AIR) to audit compliance with routine childhood vaccinations and additional vaccines (23-valent pneumococcal, human papillomavirus (HPV), and annual influenza). Data from medical records were analyzed for compliance with serologic testing (QuantiFERON TB, Hep B and C, Varicella, and Epstein-Barr virus (EBV)) before initiating IS therapy, which included immunomodulators, biologics, or small molecules. Results Of the 243 patients, 120 (52%) were diagnosed with Crohn's disease and 106 (43%) with ulcerative colitis. A total of 181 patients (74.5%) were treated with immunomodulators, while 62 (26%) received biologic therapies. Incomplete routine vaccination coverage was identified in 71 (29.2%) patients, with no notable differences observed between the IS and non-IS groups (p=0.3). Specific vaccines with incomplete coverage included HPV in 49 (24%) patients, Varicella in 39 (16%) patients, and diphtheria-tetanus-pertussis (DTP in 16 (6.5%) patients. Pre-treatment serological screening was also suboptimal, with the lowest testing rate for EBV at 32 (13.2) patients and the highest for Varicella at 181 (74.6%) patients. Conclusion The results emphasized the importance of targeted interventions to enhance vaccination and screening practices, enhancing disease management, and reducing the possibility of preventable infections in the vulnerable populace.

CureusVol. 16(11)
Princess Margaret Hospital for Children (AU), Sonic Healthcare (Germany) (DE)
Openalex Percentile: Top 24%
Inflammatory Bowel Disease
0.55
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.